查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424829

药物基因组学市场：按产品、技术、应用、最终用户划分 - 全球预测（至 2031 年）

Pharmacogenomics Market by Offering (Instrument, Consumables, Software), Technology (PCR, Sequencing, Microarray), Application (Oncology, Mental Health, Cardiology, Neurology, Infectious Disease), End User (Hospitals, Academic) - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 210 Pages | 订单完成后即时交付

价格

到 2030 年，药物基因组学市场预计将达到 195 亿美元，2024 年至 2031 年复合年增长率为 8.9%。

该报告透过广泛的一手和二手研究以及对市场情景的深入分析，探讨了关键的行业驱动因素、限制因素、挑战和机遇。 药物基因组学市场的成长是由于药物基因组学生物标记治疗应用的扩大、个性化药物采用的扩大、老年人口的增加和慢性病的患病率以及药物发现和开发的增加美国FDA 和EMA，其中包括药物基因组学资料使用的建议。 然而，个人化药物的高成本限制了该市场的成长。

此外，药物基因组学在神经系统疾病和癌症治疗中的应用不断扩大，准确度更高的新的、更先进的诊断工具的开发，以及对药物不良反应的认识不断增强，正在推动药物基因组学市场的活动。预计这将为玩家提供成长机会。 然而，对药物基因组学和个人化医疗的认识不足、对基因检测及其益处缺乏了解以及缺乏对基因检测和精准医疗的报销是影响市场成长的主要挑战。

目录

第1章简介

第2章研究方法

第 3 章执行摘要

第 4 章市场洞察

  • 摘要
  • 影响市场成长的因素
    • 市场动态
    • 因素分析
  • 主要趋势
    • 随着定序成本的下降，药物基因组学测试变得更加经济实惠
    • 人工智慧在药物基因组学领域的潜力不断增长
  • 监理分析
    • 美国
    • 加拿大
    • 欧洲
    • 中国
    • 日本
    • 印度
    • 拉丁美洲
    • 中东/非洲
  • 价格分析
  • 波特五力分析

第 5 章药物基因体学市场评估：依产品

  • 摘要
  • 消耗品
  • 设备
  • 软体与服务

第 6 章药物基因体学市场评估：依技术

  • 摘要
  • 聚合□炼式反应 (PCR)
  • 定序
  • 微阵列晶片
  • 质谱分析
  • 电泳
  • 其他技术

第 7 章全球药物基因体学市场评估：按应用

  • 摘要
  • 癌症领域
  • 心理健康
  • 传染病
  • 循环系统
  • 神经系统疾病
  • 其他用途

第 8 章药物基因体学市场评估：按最终使用者

  • 摘要
  • 医院/诊断实验室
  • 学术/研究机构
  • 其他最终用户

第 9 章药物基因体学市场评估：按地区

  • 概述
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太地区其他地区
  • 拉丁美洲
  • 中东/非洲

第10章竞争分析

  • 摘要
  • 主要成长策略
  • 竞争基准测试
  • 竞争对手仪表板
    • 行业领导者
    • 市场差异化因素
    • 领先企业
    • 新兴公司
  • 市场排名（2023 年）
    • Thermo Fisher Scientific, Inc.（美国）
    • Illumina, Inc.（美国）
    • 丹纳赫公司（美国）
    • F. Hoffmann-La Roche Ltd.（瑞士）

第 11 章公司简介（业务概览、财务概况、产品组合、策略发展、SWOT 分析）

  • F. Hoffmann La-Roche Ag
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc.
  • Pacific Biosciences of California, Inc.

（附註：将发布前 5 名公司的 SWOT 分析。）

第12章 附录

Product Code: MRHC - 104682

The pharmacogenomics market is expected to reach $19.5 billion by 2030, at a CAGR of 8.9% from 2024 to 2031.

With extensive primary and secondary research and in-depth analysis of the market scenario, the report studies the key industry drivers, restraints, challenges, and opportunities. The growth of the pharmacogenomics market is attributed to the growing therapeutic applications of pharmacogenomic biomarkers, the increasing adoption of personalized medicines, the rising geriatric population and chronic disease prevalence, and the U.S. FDA's and EMA's recommendations for using pharmacogenomic data in drug discovery & development. However, the high costs of personalized medicines restrain the growth of this market.

Furthermore, the increasing application of pharmacogenomics in the treatment of neurological disorders and cancers, the development of new, more advanced diagnostic tools with improved accuracy, and growing awareness regarding adverse drug reactions are expected to generate growth opportunities for the players operating in the pharmacogenomics market. However, low awareness about pharmacogenomics and personalized medicine, the limited understanding of genetic testing and its benefits, and the lack of reimbursements for genetic testing and precision medicine are major challenges impacting market growth.

Based on offering, the global pharmacogenomics market is segmented into consumables, instruments, and software & services. In 2024, the consumables segment is expected to account for the largest share of the market. The largest market share of this segment is attributed to the recurrent use of consumables over instruments and the high burden of chronic diseases. Moreover, the high increasing prevalence of chronic diseases coupled with the focus of players for the launch of advanced and better reagents & kits drives the segment growth.

Based on technology, the global pharmacogenomics market is segmented into polymerase chain reaction (PCR), sequencing, microarray, mass spectrometry, electrophoresis, and other technologies. In 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the pharmacogenomics market. The large market share of this segment is attributed to the high sensitivity, accuracy, low sample volume requirements, and cost-effectiveness coupled with the high presence of PCR base across all the end users, initiatives by players to launch and get approvals for new PCR products for pharmacogenomics, and a wide range of applications of the PCR.

Based on application, the global pharmacogenomics market is segmented into oncology, mental health cardiology, neurological disorders, infectious diseases, and other applications. The oncology segment is expected to register the fastest CAGR during the forecast period of 2024-2031. The fast growth of this segment is attributed to the increasing prevalence of cancer cases and the need for targeted cancer treatment, growing demand for precision oncology, and growing research activities for precision oncology.

Based on end user, the global pharmacogenomics market is segmented into hospitals & diagnostic laboratories, academic and research institutes, and other end users. In 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the global pharmacogenomics Market. The large market share of this segment is attributed to the growing adoption of precision medicine, the growing prevalence of chronic diseases, the large number of clinical trials conducted at hospitals and diagnostic laboratories, and the focus of pharmacogenomic testing services companies on acquisitions and launches of pharmacogenomic testing services. For instance, in 2023, Incite Health Pty Limited (Australia), a pharmacogenomic testing company, acquired CNSDose LLC (U.S.), a pharmacogenomic test provider.

An in-depth analysis of the geographical scenario of the pharmacogenomics market provides detailed qualitative and quantitative insights into five major geographies: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, along with the coverage of major countries in each region. Asia-Pacific is slated to register the highest CAGR during the forecast period. Rising government spending to increase testing capacities; increasing cases of inherited diseases such as Down Syndrome, cystic fibrosis, sickle cell disease, colon (colorectal) cancer, and breast cancer; growing awareness about the significance of genetic tests; and increasing government initiatives promoting genetic testing contribute to the growth of the market.

Some of the key players operating in the global pharmacogenomics market are F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), and Pacific Biosciences of California, Inc. (U.S.).

Scope of the Report:

Pharmacogenomics Market, by Offering

  • Instruments
  • Consumables
  • Software & Services

Pharmacogenomics Market, by Technology

  • Polymerase Chain Reaction
  • DNA Sequencing
  • Electrophoresis
  • Microarray
  • Mass Spectrometry
  • Other Technologies

(Note: Other Technologies include nucleic acid amplification technology and in situ hybridization)

Pharmacogenomics Market, by Application

  • Oncology
  • Mental Health
  • Cardiology
  • Neurological Disorders
  • Infectious Diseases
  • Other Applications

(Note: Other Applications include pain management, adverse drug reactions, autoimmune diseases, metabolic disorders, pulmonary diseases, hematology, dermatology, transplantation, urology, analgesia, anesthesiology, antidotal therapy, and forensic pathology)

Pharmacogenomics Market, by End User

  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Other End Users

(Other End Users include pharmaceutical & biotechnology companies, clinical research organizations (CROS), and forensic laboratories)

Pharmacogenomics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • Rest of Asia-Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America (RoLATAM)
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process Of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from The Industry
  • 2.3. Market Sizing and Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
  • 2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Market Dynamics
      • 4.2.1.1. Growing Therapeutic Applications of Pharmacogenomic Biomarkers Supporting Market Growth
      • 4.2.1.2. Increasing Adoption of Personalized Medicines Driving the Demand for Pharmacogenomics
      • 4.2.1.3. Rising Geriatric Population and Chronic Disease Prevalence Boosting Pharmacogenomic Research and Testing
      • 4.2.1.4. The U.S. FDA's And EMA's Recommendations for Using Pharmacogenomic Data in Drug Discovery & Development Accelerating Market Expansion
      • 4.2.1.5. Growing Awareness Regarding Adverse Drug Reactions (ADRs) Generating Opportunities for Market Players
      • 4.2.1.6. Low Awareness About Pharmacogenomics and Personalized Medicine to Remain a Major Challenge for Market Stakeholders
      • 4.2.1.7. Lack Of Reimbursements for Genetic Testing and Precision Medicine Impacting Market Growth
    • 4.2.2. Factors Analysis
  • 4.3. Key Trends
    • 4.3.1. Declining Costs of Sequencing Making Pharmacogenomic Testing More Affordable
    • 4.3.2. Increasing Potential of AI In Pharmacogenomics
  • 4.4. Regulatory Analysis
    • 4.4.1. U.S
    • 4.4.2. Canada
    • 4.4.3. Europe
    • 4.4.4. China
    • 4.4.5. Japan
    • 4.4.6. India
    • 4.4.7. Latin America
    • 4.4.8. Middle East & Africa
  • 4.5. Pricing Analysis
  • 4.6. Porter's Five Forces Analysis
    • 4.6.1. Bargaining Power of Buyers
    • 4.6.2. Bargaining Power of Suppliers
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Degree Of Competition

5. Pharmacogenomics Market Assessment-by Offering

  • 5.1. Overview
  • 5.2. Consumables
  • 5.3. Instruments
  • 5.4. Software & Services

6. Pharmacogenomics Market Assessment-by Technology

  • 6.1. Overview
  • 6.2. Polymerase Chain Reaction (PCR)
  • 6.3. Sequencing
  • 6.4. Microarray
  • 6.5. Mass Spectrometry
  • 6.6. Electrophoresis
  • 6.7. Other Technologies

7. Global Pharmacogenomics Market Assessment-by Application

  • 7.1. Overview
  • 7.2. Oncology
  • 7.3. Mental Health
  • 7.4. Infectious Diseases
  • 7.5. Cardiology
  • 7.6. Neurological Disorders
  • 7.7. Other Applications

8. Pharmacogenomics Market Assessment-by End User

  • 8.1. Overview
  • 8.2. Hospitals & Diagnostic Laboratories
  • 8.3. Academic & Research Institutes
  • 8.4. Other End Users

9. Pharmacogenomics Market Assessment-by Geography

  • 9.1. Overview
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. U.K.
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Rest Of Europe
  • 9.4. Asia-Pacific
    • 9.4.1. China
    • 9.4.2. Japan
    • 9.4.3. India
    • 9.4.4. Rest Of Asia-Pacific
  • 9.5. Latin America
  • 9.6. Middle East & Africa

10. Competition Analysis

  • 10.1. Overview
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Competitive Dashboard
    • 10.4.1. Industry Leaders
    • 10.4.2. Market Differentiators
    • 10.4.3. Vanguards
    • 10.4.4. Emerging Companies
  • 10.5. Market Ranking (2023)
    • 10.5.1. Thermo Fisher Scientific, Inc. (U.S.)
    • 10.5.2. Illumina, Inc. (U.S.)
    • 10.5.3. Danaher Corporation (U.S.)
    • 10.5.4. F. Hoffmann-La Roche Ltd. (Switzerland)

11. Company Profiles (Business Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)

  • 11.1. F. Hoffmann La-Roche Ag
  • 11.2. Thermo Fisher Scientific, Inc.
  • 11.3. Illumina, Inc.
  • 11.4. Danaher Corporation
  • 11.5. Agilent Technologies, Inc.
  • 11.6. Qiagen N.V.
  • 11.7. Abbott Laboratories
  • 11.8. Bio-Rad Laboratories, Inc.
  • 11.9. PerkinElmer, Inc.
  • 11.10. Pacific Biosciences of California, Inc.

(Note: SWOT Analysis of Top 5 Companies Will Be Provided)

12. Appendix

  • 12.1. Available Customization
  • 12.2. Related Reports
  • Table 1 Pharmacogenomics Instruments: Pricing
  • Table 2 Global Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 3 Global Pharmacogenomic Consumables Market, by Country/Region, 2022-2031 (USD Million)
  • Table 4 Global Pharmacogenomic Instruments Market, by Country/Region, 2022-2031 (USD Million)
  • Table 5 Global Pharmacogenomic Software & Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 6 Advantages and Disadvantages of Technologies for Pharmacogenomics
  • Table 7 Global Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 8 Global Pharmacogenomics Market for Polymerase Chain Reaction, by Country/Region, 2022-2031 (USD Million)
  • Table 9 Global Pharmacogenomics Market for Sequencing, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global Pharmacogenomics Market for Microarrays, by Country/Region, 2022-2031 (USD Million)
  • Table 11 Global Pharmacogenomics Market for Mass Spectrometry, by Country/Region, 2022-2031 (USD Million)
  • Table 12 Global Pharmacogenomics Market for Electrophoresis, by Country/Region, 2022-2031 (USD Million)
  • Table 13 Global Pharmacogenomics Market for Other Technologies, by Country/Region, 2022-2031 (USD Million)
  • Table 14 Global Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 15 Number of New Cancer Cases, by Region, 2020 Vs. 2040 (In Million)
  • Table 16 Global Pharmacogenomics Market for Oncology, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Global Pharmacogenomics Market for Mental Health, by Country/Region, 2022-2031 (USD Million)
  • Table 18 HIV Statistics (2021)
  • Table 19 Global Pharmacogenomics Market for Infectious Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Global Pharmacogenomics Market for Cardiology, by Country/Region, 2022-2031 (USD Million)
  • Table 21 Global Pharmacogenomics Market for Neurological Disorders, by Country/Region, 2022-2031 (USD Million)
  • Table 22 Global Pharmacogenomics Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
  • Table 23 Global Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 24 Global Pharmacogenomics Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2022-2031 (USD Million)
  • Table 25 Global Pharmacogenomics Market for Academic & Research Institutes, by Country/Region, 2022-2031 (USD Million)
  • Table 26 Global Pharmacogenomics Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
  • Table 27 Global Pharmacogenomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 28 North America: Pharmacogenomics Market, by Country, 2022-2031 (USD Million)
  • Table 29 North America: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 30 North America: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 31 North America: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 32 North America: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 33 U.S.: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 34 U.S.: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 35 U.S.: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 36 U.S.: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 37 Canada: Diabetes Prevalence 2023 Vs 2033
  • Table 38 Canada: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 39 Canada: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 40 Canada: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 41 Canada: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 42 Europe: Ubiquitous Pharmacogenomics Contributions (USD Million)
  • Table 43 Europe: Pharmacogenomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 44 Europe: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 45 Europe: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 46 Europe: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 47 Europe: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 48 Germany: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 49 Germany: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 50 Germany: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 51 Germany: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 52 France: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 53 France: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 54 France: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 55 France: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 56 U.K. Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 57 U.K. Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 58 U.K. Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 59 U.K. Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 60 Italy: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 61 Italy: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 62 Italy: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 63 Italy: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 64 Spain: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 65 Spain: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 66 Spain: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 67 Spain: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 68 Rest of Europe: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 69 Rest of Europe: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 70 Rest of Europe: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 71 Rest of Europe: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 72 Asia-Pacific: Pharmacogenomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 73 Asia-Pacific: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 74 Asia-Pacific: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 75 Asia-Pacific: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 76 Asia-Pacific: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 77 China: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 78 China: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 79 China: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 80 China: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 81 Japan: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 82 Japan: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 83 Japan: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 84 Japan: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 85 India: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 86 India: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 87 India: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 88 India: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 89 Rest of Asia-Pacific: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 90 Rest of Asia-Pacific: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 91 Rest of Asia-Pacific: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 92 Rest of Asia-Pacific: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 93 Latin America: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 94 Latin America: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 95 Latin America: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 96 Latin America: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 97 Middle East & Africa: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 98 Middle East & Africa: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 99 Middle East & Africa: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 100 Middle East & Africa: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 101 Recent Developments, by Company (2020-2023)

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Secondary Sources Referenced for This Study
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
  • Figure 6 Market Sizing and Growth Forecast Approach
  • Figure 7 Global Pharmacogenomics Market, by Offerings, 2024 Vs. 2031 (USD Million)
  • Figure 8 Global Pharmacogenomics Market, by Technology, 2024 Vs. 2031 (USD Million)
  • Figure 9 Global Pharmacogenomics Market, by Application, 2024 Vs. 2031 (USD Million)
  • Figure 10 Global Pharmacogenomics Market, by End User, 2024 Vs. 2031 (USD Million)
  • Figure 11 Global Pharmacogenomics Market, by Geography
  • Figure 12 Impact Analysis of Market Dynamics
  • Figure 13 Percentage Share of U.S. FDA-Approved PGx-Labeled Drugs, by Application (As of June 2023)
  • Figure 14 U.S.: Number of Personalized Medicines on The Market, 2008-2020
  • Figure 15 Molecular and Cell-Based Therapies (As a Percentage of Total FDA-Approved Therapies), 2015-2021
  • Figure 16 Global Estimated Number of New Cancer Cases, 2020-2040 (In Million)
  • Figure 17 Genome Sequencing Costs, 2010-2022 (USD)
  • Figure 18 USFDA Regulatory Pathways for Pharmacogenomics Products
  • Figure 19 EU Regulatory Pathway - IVDR 2017/746
  • Figure 20 China: Medical Device Classification and Pre-Market Requirements for IVD Devices
  • Figure 21 Porter's Five Forces Analysis
  • Figure 22 Global Pharmacogenomics Market, by Offering, 2024 Vs. 2031 (USD Million)
  • Figure 23 Global Estimated Number of New Cancer Cases (2020-2040) (Million)
  • Figure 24 Global Pharmacogenomics Market, by Technology, 2024 Vs. 2031 (USD Million)
  • Figure 25 Global Pharmacogenomics Market, by Application, 2024 Vs. 2031 (USD Million)
  • Figure 26 Estimated Number of New Cancer Cases, 2020 Vs. 2040
  • Figure 27 Global Pharmacogenomics Market, by End User, 2023 Vs. 2030 (USD Million)
  • Figure 28 Global Pharmacogenomics Market Assessment, by Country/Region, 2024-2031 (USD Million)
  • Figure 29 North America: Pharmacogenomics Market Snapshot
  • Figure 30 Precision Medicine Research Funding To NIH, 2018-2024 (USD Million)
  • Figure 31 Europe: Pharmacogenomics Market Snapshot
  • Figure 32 Germany: Estimated Number of New Cancer Cases, 2020-2035 (In Thousand)
  • Figure 33 France: Total Number of People with Dementia, 2018-2050 (In Thousands)
  • Figure 34 Asia-Pacific: Pharmacogenomics Market Snapshot
  • Figure 35 Key Growth Strategies Adopted by Leading Market Players (2020-2023)
  • Figure 36 Pharmacogenomics Market: Competitive Benchmarking, by Offering
  • Figure 37 Pharmacogenomics Market: Competitive Benchmarking, by Region
  • Figure 38 Competitive Dashboard: Pharmacogenomics Market
  • Figure 39 Global Pharmacogenomics Market Ranking, by Key Players (2023)
  • Figure 40 F. Hoffmann La-Roche Ltd.: Financial Snapshot (2022)
  • Figure 41 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
  • Figure 42 Illumina, Inc.: Financial Overview (2022)
  • Figure 43 Danaher Corporation: Financial Overview (2022)
  • Figure 44 Agilent Technologies, Inc.: Financial Snapshot (2023)
  • Figure 45 Qiagen N.V.: Financial Snapshot (2022)
  • Figure 46 Abbott Laboratories: Financial Overview (2022)
  • Figure 47 Bio-Rad Laboratories, Inc.: Financial Overview (2022)
  • Figure 48 PerkinElmer, Inc.: Financial Overview (2022)
  • Figure 49 Pacific Biosciences of California, Inc.: Financial Overview (2022)